Antithrombotic Therapy in AF Patients Undergoing PCI

Slides:



Advertisements
Similar presentations
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
Advertisements

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
The patient with atrial fibrillation who needs PCI
Denise Sutter, PharmD, BCPS
Role of LAA Occlusion in Patients With Atrial Fibrillation After PCI Marco Mennuni, MD Interventional Cardiologist Hopital Europeen George Pompidou,
When should aspirin be dropped from triple therapy?
Addressing the Challenges in Primary and Secondary Stroke Prevention
DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.
European and US Guidelines
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
(p < for group 1 or 2 vs. group 3)
Atrial Fibrillation and PCI
Anticoagulants in Interventional Cardiology:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Achieving Long-Term Protection Post-MI
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Up to Date on Which NOAC for Which Patient
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Through Thick and Thin.
New Perspectives in CAD and PAD: Weighing the Latest Evidence
What Has Been Tried and What Is True?
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
The Essentials for Secondary Stroke Prevention
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
New Oral Anticoagulants and VTE Management
VTE Treatment Conventional Approach
NOACS: Emerging data in ACS/IHD
Efficacy and Safety of Edoxaban in Patients With AF and HF
AF and PCI in Practice.
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
What Anticoagulant Registries Are Revealing
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
Oral Anticoagulation in AF
Dos and Don’ts for High-Risk Elderly Patients With AF
Extraordinary Cases of VTE Prevention in Patients With Cancer
Anticoagulation and Thrombosis Management
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
Duration of Dual Antiplatelet Therapy
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
What You Didn't Know About AF and Renal Dysfunction
Cancer-Associated Thrombosis
A Case Challenge.
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Antithrombotics in Arterial Disease: Focus on Coronary Disease
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
An Unmet Need.
5 Good Minutes on Atrial Fibrillation-related Stroke
ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.
NOACs and Reversal Agents
(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
ESC Guideline on the Management of STEMI Recommendation for DAPT
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Antithrombotic Therapy in AF Patients Undergoing PCI

Epidemiology

How to Reduce the Probability of a Major Bleeding Complication?

Patients with AF Undergoing PCI Meta-Analysis – NOACs vs VKA

ENTRUST-AF PCI Study Design

ENTRUST-AF PCI Outcomes

ENTRUST-AF PCI Edoxaban Dose Reduction Criteria

ENTRUST-AF PCI Landmark Analysis for Primary Endpoint After Day 14

Meta-Analysis of DAPT vs TAPT Stent Thrombosis

Recommendations for OAC and Antiplatelet Therapy in AF Undergoing PCI

ENTRUST-AF PCI Baseline Patient Characteristics

WOEST VKA in Patients With AF Undergoing PCI

Network of 4 Antithrombotic Treatment Regimens

What Have We Learned?

Selecting a NOAC

PIONEER Incidence of MACEs With Rivaroxaban vs VKA

RE-DUAL Efficacy Endpoints for Dabigatran vs VKA

What Next?

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.